Discover personalized clinical trial options designed to support your journey, safely, confidentially, and at no cost.
Takes less than 2 minutes • 100% confidential
Breast cancer is the most common cancer in women worldwide, arising from cells in the breast that gr…
New breast lump, Size/shape change, Skin dimpling and more.
BRCA1 / BRCA2 gene mutations (hereditary); Dense breast tissue.
Surgery, Radiation Therapy and more.
Symptoms
Common Symptoms
Quality of Life Impact
Treatment affects body image, fertility, fatigue, and emotional wellbeing. With comprehensive survivorship care, most patients return to full activity. Peer support and PAG involvement are key to long-term quality of life.
With the right care and support, most people live full, active lives.
Causes & Risk Factors
Health Insights
Active Global Trials
91+
Across all phases
Symptom Frequency
78%
Patients report primary symptom
Trial Improvement Rate
68%
Report improvement within 3 months
Avg. Trial Duration
14 mo
Median length of participation
Symptom Frequency Among Patients
Treatment
Lumpectomy (breast-conserving) or mastectomy, often combined with sentinel lymph node biopsy.
Typically after lumpectomy to reduce local recurrence risk.
Tamoxifen or aromatase inhibitors for ER+ cancers, taken 5–10 years.
Trastuzumab (Herceptin), pertuzumab, T-DM1 for HER2+ disease.
Neoadjuvant or adjuvant, anthracyclines and taxanes are backbone regimens.
Olaparib / talazoparib for BRCA-mutated early or metastatic breast cancer.
Clinical Trials
Merck Sharp & Dohme
Evaluating whether adding pembrolizumab to chemotherapy improves outcomes in HER2-negative breast cancer.
NCT05723489
AstraZeneca
Evaluating olaparib as maintenance therapy for BRCA1/2 mutated HER2-negative metastatic breast cancer.
NCT05312904
Daily Life
You are not alone. Millions of people navigate this condition every day, and with the right support system and treatments, a meaningful life is absolutely within reach.
Community Support
Connect with thousands of patients and caregivers
Digital Tools
Track symptoms and share insights with your care team
Specialist Network
Access to leading neurologists and researchers
Education Hub
Evidence-based resources tailored to your journey
Why Join a Trial
Try innovative therapies before they're widely available, some with breakthrough potential.
Receive close monitoring and support from leading specialists throughout the trial.
Study-related care, tests, and the investigational treatment are provided at no charge.
Research Pipeline
Current pipeline overview for Breast Cancer
Pipeline data is indicative. Source: ClinicalTrials.gov & WHO ICTRP.
Patient Stories
“I didn't know clinical trials were free. HEKMA changed everything about how I understood my options.”
James T.
✓ In remission“I didn't know clinical trials were free. HEKMA changed everything about how I understood my options.”
James T.
✓ In remissionPublished with patient consent. Details may be anonymised.
News
European Medicines Agency Approves Pembrolizumab in Triple-Negative Breast Cancer
The EMA approved pembrolizumab (Keytruda) in combination with chemotherapy for locally recurrent unresectable or metastatic triple-negative breast cancer.
EMA · Feb 28, 2025
FAQ
Resources
